 The screening period will be performed within a 2 week period, followed by a treatment period of investigational visits which will occur weekly from Day 0 Visit 1 until week 12, then 4 weeks later at week 16, and then at 8-weekly intervals until study participants reach documented progression of disease criteria for both LPFS and PFS which marks the end of study participation i.e. EOS visit. 